

NPCA, Clinical Effectiveness Unit

Royal College of Surgeons of England 35-43 Lincoln's Inn Fields London WC2A 3PE

<u> ∭@NPCA_uk</u> T: 020 7869 6601 E: <u>npca@rcseng.ac.uk</u> W: <u>www.npca.org.uk</u>

NPCA Newsletter, Summer 2020



Annual Report 2020

Thank you to all members of Trust teams who collected and submitted data for this year's Annual Report. The production of the report is currently in progress by the NPCA team.

Please find enclosed a data summary of the final cancer registration dataset with the number of patients allocated to the Trust where the patients were diagnosed between 1 April 2018 and 31 March 2019. The table also includes the completeness of the data items describing key patient and tumour characteristics.

The cancer registration dataset set can no longer be changed, but we really need your feedback. It will help us to interpret the results of our analyses so that we can add an explanation in the Annual Report. Please check the data that we have for your Trust. If you think the number of men allocated to your Trust at diagnosis is incorrect please inform the NPCA team via email <u>npca@rcseng.ac.uk</u> by Friday 24th July 2020. Also, please let us know if the completeness of data items in your Trust is lower than expected.

We are working towards publication of the report and provider-level results in January 2021. In keeping with HQIP and NHSE's updated Standard Reporting Procedure (SRP) we do not have a confirmed date for publication of the report. Please check our website for updates.



NPCA Performance Indicators 2020

In the Annual Report 2020, the following three performance indicators will be reported for each Specialist Multidisciplinary Team (related to the Trust where a patient was diagnosed):

- The proportion of men with metastatic prostate cancer at diagnosis
- The proportion of men with low-risk localised prostate cancer undergoing radical prostate cancer therapy
- The proportion of men with high-risk/locally advanced disease receiving radical prostate cancer therapy

The following indicators will be reported for each Trust that provides radiotherapy:

- The proportion of men with high-risk/locally advanced disease receiving prostate and pelvic lymph node irradiation
- The proportion of men experiencing a severe bowel complication requiring an intervention following external beam radiotherapy

The following indicators will be reported for each Trust that carries out radical prostate cancer surgery:

- The proportion of patients who had an emergency readmission within 90 days of radical prostatectomy
- The proportion of men experiencing a severe urinary complication requiring an intervention following radical prostatectomy



Detection and Management of Outliers

The NPCA team has started the production of this year's Annual Report (2020). We will contact your unit in October 2020 if a performance indicator for your unit is not within an acceptable range. The steps we will follow are outlined in the NPCA Outlier Policy for 2020.


Please visit the <u>NPCA website</u> regularly and check the NPCA Outlier Policy for updates in light of COVID-19.



This email was sent to you by the National Prostate Cancer Audit, Royal College of Surgeons of England, 35-43 Lincoln's Inn Fields, London WC2A.

To ensure continued receipt of our emails please add us to your address book or safe list.

In accordance with the General Data Protection Regulation (GDPR), the Royal College of Surgeons of England is committed to protecting your privacy. If you wish to know more please access the RCS privacy policy. If you no longer wish to receive any messages please unsubscribe. © RCS 2020, Registered Charity No. 212808



NPCA, Clinical Effectiveness Unit

Royal College of Surgeons of England 35-43 Lincoln's Inn Fields London WC2A 3PE

T: 020 7869 6601 🕑 @<u>NPCA_uk</u> E: <u>npca@rcseng.ac.uk</u> W: <u>www.npca.org.uk</u>



NPCA Patient Information

The NPCA Patient Summary 2020 is now <u>online</u>! This summary report was developed in consultation with the newly formed NPCA Patient and Public Involvement (PPI) Forum, which met for the first time in April 2020. Further to a suggestion from the NPCA PPI Forum, we have developed a series of <u>Patient Summary Slide Sets</u> that can be used during patient support groups and are freely available to download from our website:

- Key results from the NPCA 2019 Annual Report
- The NPCA Patient Survey
- How to read a funnel plot

NPCA Publications in 2020

Risk stratification for prostate cancer management: value of the Cambridge Prognostic Group classification for assessing treatment allocation	BMC Medicine 2020, 18(1):1-9.	
<u>Comparison of complications after transrectal and</u> <u>transperineal prostate biopsy: a national population-based</u> <u>study</u>	BJU international 2020 , Mar 2 Epub	
Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.	Journal of Clinical Oncology 2020, 38(7):744-752.	
<u>Comparison of treatment-related toxicity with hypofractionated or</u> <u>conventionally fractionated radiation therapy for prostate cancer: a</u> <u>national population-based study</u>	Clinical Oncology 2020, 32 (8): 501-508	

On behalf of the NPCA Project Team

T: 020 7869 6601

♥ @<u>NPCA_uk</u>

Please contact us or visit our website for more information about the NPCA.

E: <u>npca@rcseng.ac.uk</u>

W: <u>www.npca.org.uk</u>

This email was sent to you by the National Prostate Cancer Audit, Royal College of Surgeons of England, 35-43 Lincoln's Inn Fields, London WC2A.

To ensure continued receipt of our emails please add us to your address book or safe list.

In accordance with the General Data Protection Regulation (GDPR), the Royal College of Surgeons of England is committed to protecting your privacy. If you wish to know more please access the <u>RCS privacy policy</u>. If you no longer wish to receive any messages please <u>unsubscribe</u>. © RCS 2020, Registered Charity No. 212808